Wilms' Tumor

Wilms' Tumor

National Organization for Rare Disorders, Inc.

Important

It is possible that the main title of the report Wilms' Tumor is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.

Synonyms

  • Embryoma Kidney
  • Embryonal Adenomyosarcoma Kidney
  • Embryonal Carcinosarcoma Kidney
  • Embryonal Mixed Tumor Kidney
  • Nephroblastoma

Disorder Subdivisions

  • None

General Discussion

Wilms' tumor is the most common form of kidney cancer in children, accounting for 6 to 8 percent of all childhood cancers. About 500 new cases are diagnosed in the USA per year. The exact cause is not known, although it is thought that in 10-15% of affected individuals, one or more mutated genes create a predisposition to Wilms' tumor.



Typically, this disease first appears when the affected child is about three years old. Wilms' tumor can often be treated successfully, depending on the stage of the tumor at detection and the age and general health of the child.

Symptoms

In the early stages, Wilms' tumor usually has no apparent symptoms. It may remain undetected until a parent or pediatrician notices a mass (lump) in the child's abdomen. Later signs may include blood in the urine, low-grade fever, loss of appetite, paleness, weight loss, and lethargy. There may be intermittent stomach pain, nausea and vomiting, as well as general discomfort (malaise). These symptoms could be due to a variety of other disorders, but parents who observe such symptoms should consult a doctor promptly.



For reasons that have to do with the genetics of Wilms' tumor, children born with an undeveloped or underdeveloped iris (aniridia), the membrane that controls for the amount light entering the eye and for the color of eye, may be predisposed to Wilms' tumor. The same is true of children born with one side of the body considerably larger than the other (hemihypertrophy). The diagnosis should also be suspected if the newborn presents with the opening of the urethra on the underside of the penis or if one or both testicles are undescended.

Causes

The exact causes of Wilms' tumor are not known at this time, but both genetic and non-genetic factors are of interest.



All cases of Wilms' tumor involve a "bunch" or "bundle" of leftover embryonic kidney cells (called nephrogenic rests) that, for some reason, did not develop at the same time as the other embryonic cells.



The location of these embryonic cells in the kidney appears to have an effect on the course of the disease. For example, if the embryonic cells are located within the kidney (intralobar), it is almost inevitable that the tumor involves only one kidney. However, if the embryonic cells are located on the edge of the kidney (perilobar), it is more likely that the tumor will invade both kidneys.



The genetic mutations associated with Wilms' tumor appear to be random (sporadic) rather than inherited from parent to child (familial) in most cases. Only a very small percentage of cases of Wilms' tumors are thought to be familial.

Affected Populations

Wilms' tumor accounts for about six to eight percent of all childhood cancers in the USA. The disorder affects one child in about 100,000 in the United States under the age of 15, so that about 450-500 new cases are seen each year. The onset of Wilms' tumor occurs mainly in children under the age of seven, with most cases developing between the ages of one and four years of age.



There are slightly fewer males than females among children in whom the disorder affects only one kidney. Significantly more females than males have the bilateral disease (both kidneys are affected).

Standard Therapies

Diagnosis

The investigation of a suspected case of Wilms' tumor usually begins with an ultrasound scan that offers a wide-angle view of the abdominal organs and usually picks up any anomalies that require further investigation. CAT scans of the chest, abdomen and pelvis usually follow in order that suspected tumors and/or tumor cells that have spread from the original site (metastasized) may be better visualized.



Treatment will be determined by the condition (staging) of the tumor. Methods of staging have been developed by the National Wilms' Tumor Study Group (NWTSG).



Staging and Treatment

Stage I. The tumor is limited to the kidney without spreading to other organs, and it has been removed completely. Stage I tumors make up about 40% of all diagnosed Wilms' tumors.



Stage II. Examination of the tumor cells (histology) is favorable, but the tumor has spread to areas around the kidney. Surgical removal is followed by chemotherapy or both radiation therapy and chemotherapy. Stage II tumors make up about 23% of all diagnosed Wilms' tumors.



Stage III. The tumor has spread to areas around the kidney including blood vessels and lymph nodes and/or other organs, making it impossible to remove all of the tumor tissue by surgery. Treatment consists of surgery followed by both radiation therapy and chemotherapy. If the tumor has grown so large that surgical removal is too risky, chemotherapy to reduce the size or bulk of the tumor tissue is tried. Stage III tumors also make up about 23% of all diagnosed Wilms' tumors.



Stage IV. The tumor has spread to organs distant from the kidney, such as lungs, liver, bone and brain. Stage IV patients are treated aggressively by surgical, radiological and chemotherapeutic means. Stage IV tumors make up about 10% of all diagnosed Wilms' tumors.



Stage V. In this stage, tumors are found in both kidneys, each of which is staged separately. Such tumors make up about 5% of all diagnosed Wilms' tumors.



Children treated for Wilms' tumor are usually considered cured if they survive for two years without any sign that the disease has returned. The small number of children with aggressive cell types, or with widespread disease at the time of diagnosis have a poorer outlook, but many of these patients are curable with intensive therapy.

Investigational Therapies

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government website.



For information about clinical trials being conducted at the National Institutes of Health (NIH) in Bethesda, MD, contact the NIH Patient Recruitment Office:



Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov



For information about clinical trials sponsored by private sources, contact:

www.centerwatch.com



The National Wilms' Tumor Study Late Effects, sponsored by Emory University, is being conducted to serve as a resource for Wilms' tumor patients and their families. Information is being collected from as many participants as possible to determine whether they or their offspring might be at risk for any adverse medical conditions. For information, contact Dollicia David at (404) 785-3633 or Dollicia.David@choa.org.



St. Jude's Children's Research Hospital is studying ways to improve the outcome for children with recurrent Wilms' tumor. A drug called topotecan has shown promising results in previous studies to treat children with other types of cancer. Now, research is being conducted to determine whether this drug may be an effective treatment for children with Wilms' tumor. For information, contact Jeffrey S. Dome, MD, at (866) 278-5833 or info@stjude.org.



The National Wilms' Tumor Study (NWTS) was conducted by a national consortium of hospitals and clinics for the purpose of carrying out controlled clinical trials of new treatments for Wilms' tumor. Findings of this study are the basis for treatment standards for Wilms' tumor patients in the United States.

References

TEXTBOOKS

Beers MH, Berkow R., eds. The Merck Manual, 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:2364.



Berkow R., ed. The Merck Manual-Home Edition.2nd ed. Whitehouse Station, NJ: Merck Research Laboratories; 2003:1622-23.



Raghaven D, Brecher ML, Johnson DH. Textbook of Uncommon Cancer. 2nd ed. John Wiley & Sons. New York, NY; 1999:21-27.



Blowey D. Denys-Drash Syndrome. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:686.



Blowey D. WAGR Syndrome. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:699.



REVIEW ARTICLES

Narchi H. Risk of Wilms' tumour with multicystic kidney disease: a systematic review. Arch Dis Child. 2005;90:147-49.



Ruteshouser EC, Huff V. Familial Wilms' tumor. Am J Med Genet C Semin Med Genet. 2004;129:29-34.



Glick RD, Hicks MJ, Nuchtern JG, et al. Renal tumors in infants less than 6 months of age. J Pediatr Surg. 2004;39:522-25.



Kalpurakal JA, Dome JS, Perlman EJ, et al. Management of Wilms' tumour: current parctice and future goals. Lancet Oncol. 2004;5:37-46.



Firoozi F, Kogan BA. Follow-up and management of recurrent Wilms' tumor. Urol Clin North Am. 2003;30:869-79.



Menke AL, Schedl A. WT1 and glomerular function. Semin Cell Dev Biol. 2003;14:233-40.



Kundu RV, Frieden IJ. Presence of vascular anomalies with congenital hemihypertrophy and Wilms' tumor: an evidence-based evaluation. Pediatr Dermatol. 2003;20:199-206.



Wagner KD, Wagner N, Schedl A. The complex life of WT1. J Cell Sci. 2003;116(Pt 9):1653-58.



Ellisen LW. Regulation of gene expression by WT1 in development and tumorigenesis. Int J Hematol. 2002;76:110-16.



FROM THE INTERNET

Blackman S. Wilms' Tumor. Medical Encyclopedia. MedlinePlus. Update date: 4/23/2004. 3pp.

www.nlm.nih.gov/medlineplus/ency/article/001575.htm



Wilms' Tumor. MedlinePlus. Date last updated: 13 January 2005. 2pp. http://www.nlm.nih.gov/medlineplus/wilmstumor.html



Dome JS, Huff V. Wilms Tumor Overview. GENEReviews. Last Revision: 24 May 2004. 18pp.

www.geneclinics.org; www.genetests.org



Wilms' Tumor and Other Childhood Kidney Tumors. (PDQ®) Patient Version. National Cancer Institute. NIH. Last Modified 12/16/2004. 8pp.

www.cancer.gov/cancertopics/pdq/treatment/wilms/patient/allpages/print

Resources

The Arc

1825 K Street NW, Suite 1200

Washington, DC 20006

Tel: (202)534-3700

Fax: (202)534-3731

Tel: (800)433-5255

TDD: (817)277-0553

Email: info@thearc.org

Internet: http://www.thearc.org



American Kidney Fund, Inc.

11921 Rockville Pike

Suite 300

Rockville, MD 20852

USA

Tel: (800)638-8299

Email: helpline@kidneyfund.org

Internet: http://www.kidneyfund.org



American Childhood Cancer Organization

10920 Connecticut Ave

Suite A

Kensington, MD 20895

Tel: (301)962-3520

Fax: (301)962-3521

Tel: (800)366-2223

Email: staff@acco.org

Internet: http://www.candlelighters.org



National Kidney Foundation

30 East 33rd Street

New York, NY 10016

Tel: (212)889-2210

Fax: (212)689-9261

Tel: (800)622-9010

Email: info@kidney.org

Internet: http://www.kidney.org



American Cancer Society, Inc.

250 Williams NW St

Ste 6000

Atlanta, GA 30303

USA

Tel: (404)320-3333

Tel: (800)227-2345

TDD: (866)228-4327

Internet: http://www.cancer.org



Childhood Cancer Canada Foundation

21 St. Clair Avenue East, Suite 801

Toronto

Ontario, M4T 1L9

Canada

Tel: 4164896440

Fax: 4164899812

Tel: 8003631062

Email: info@childhoodcancer.ca

Internet: http://www.childhoodcancer.ca



International WAGR Syndrome Association

1218 Wooded Knoll

San Antonio, TN 78258

USA

Email: reachingout@wagr.org

Internet: http://www.wagr.org/



Rare Cancer Alliance

1649 North Pacana Way

Green Valley, AZ 85614

USA

Internet: http://www.rare-cancer.org



Aniridia Network UK

22 Cornish House

Adelaide Lane

Sheffield, S3 8BJ

United Kingdom

Tel: 4407792867949

Email: info@aniridia.org.uk

Internet: http://www.aniridia.org.uk



Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Internet: http://rarediseases.info.nih.gov/GARD/



Madisons Foundation

PO Box 241956

Los Angeles, CA 90024

Tel: (310)264-0826

Fax: (310)264-4766

Email: getinfo@madisonsfoundation.org

Internet: http://www.madisonsfoundation.org



Friends of Cancer Research

1800 M Street NW

Suite 1050 South

Washington, DC 22202

Tel: (202)944-6700

Email: info@focr.org

Internet: http://www.focr.org



Cancer.Net

American Society of Clinical Oncology

2318 Mill Road Suite 800

Alexandria, VA 22314

Tel: (571)483-1780

Fax: (571)366-9537

Tel: (888)651-3038

Email: contactus@cancer.net

Internet: http://www.cancer.net/



Cancer Support Community

1050 17th St NW Suite 500

Washington, DC 20036

Tel: (202)659-9709

Fax: (202)974-7999

Tel: (888)793-9355

Internet: http://www.cancersupportcommunity.org/



Lance Armstrong Foundation

2201 E. Sixth Street

Austin, TX 78702

Tel: (512)236-8820

Fax: (512)236-8482

Tel: (877)236-8820

Email: media@livestrong.org

Internet: http://www.livestrong.org



For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use . How this information was developed to help you make better health decisions.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.